Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.71986 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 27.05.2026. Verfasst von Wenjing Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Central Nervous System Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Incubation Project (Beijing Chao-Yang Hospital, Capital Medical University.
Abstract (Originalsprache)
Background
Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM), with limited data on its clinical characteristics and prognosis. This multicenter study characterizes the largest Chinese cohort of MM patients with CNS involvement (MM‐CNS) to date.
Methods
We conducted a multicenter retrospective study across nine hematology centers in China (July 2017–June 2024), analyzing clinical records of MM‐CNS patients. Data collection encompassed diagnostic parameters, treatment regimens, and survival outcomes.
Results
Among 35 identified MM‐CNS cases (median age 55 years, range 40–83), CNS manifestations presented at initial MM diagnosis in 31.4% (11/35) versus relapse in 68.6% (24/35), with median latency of 22.8 months from MM diagnosis. Predominant features included IgG subtype (51.4%), λ light chain restriction (54.3%), and high‐risk cytogenetics: 1q21 amplification (48.3%), t(4;14) translocation (13.8%), and complex karyotypes of chromosome (35.7%). Diagnostic confirmation combined CSF analysis (protein elevation, plasma cell detection) with neuroimaging (meningeal/parenchymal lesions). Treatments included systemic chemotherapy (88.6%), intrathecal therapy (51.4%), radiotherapy (17.1%), chimeric antigen receptor T‐cell (CAR‐T) therapy (11.4%), and autologous stem cell transplantation (ASCT) (14.3%). Despite 62.9% overall response rate (36.4% complete remission), 56% relapsed within median 3.1 months (range 1.2–8.4). The median follow‐up duration was 19.1 months (range: 0.1–46.8). Median overall survival (OS) at 13.0 months (range 0.1–43.1) with 60% mortality (21/35).
Conclusions
CNS involvement in MM is associated with aggressive disease and poor prognosis. Despite transient responses to multimodal therapies, rapid progression and high mortality persist. Novel strategies are urgently needed to improve outcomes in this high‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
- Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Hematology, Sinopharm Tongmei General Hospital, DaTong, China.
- Department of Hematology, Linfen People's Hospital, Linfen, China.
- Department of Hematology, First Hospital of Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Wenjing Li, Lan Zhang, Honghu Zhu, Wenming Chen, Wen Gao
Förderung
- National Natural Science Foundation of China
- Clinical Research Incubation Project (Beijing Chao-Yang Hospital, Capital Medical University
Zitieren
APA
Li, W., Tian, W., Ma, J., Li, L., Li, Z., Liu, J., Gao, G., Xi, Z., Zhang, L., Zhang, W., Duan, L., Geng, H., Meng, J., Zhu, H., Chen, W., & Gao, W. (2026). Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.71986
Vancouver
Li W, Tian W, Ma J, Li L, Li Z, Liu J, et al. Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.71986
BibTeX
@article{Li2026,
author = {Li, Wenjing and Tian, Weiwei and Ma, Jie and Li, Linyu and Li, Zhihua and Liu, Jie and Gao, Guorong and Xi, Zhenfang and Zhang, Lan and Zhang, Weihua and Duan, Lixiang and Geng, Hui and Meng, Jie and Zhu, Honghu and Chen, Wenming and Gao, Wen},
title = {Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.71986}
}
EUVIMED